Home › Current trials › Panic Disorder Study
RECRUITMENT ON HOLD
Panic Disorder Study
The study is evaluating a potential new oral treatment for adults with panic disorder, a mental health condition marked by sudden and repeated episodes of intense fear, often accompanied by physical symptoms like chest pain, shortness of breath, and rapid heartbeat.
Recruitment for this study is currently on hold.
We’re not accepting new enquiries for this study at the moment. The information below is provided for reference. To be notified if recruitment reopens, or about other studies that may suit you, join our participant register.
ABOUT THIS STUDY
About the treatment
The investigational treatment combines two approved medications that are not approved for panic attacks into a unique formulation designed to target brain pathways involved in the stress response, aiming to regulate the physiological and neurological factors that contribute to panic attacks. In earlier research, it showed promising results, including reduced panic attacks and good tolerability.
This clinical trial aims to assess the safety and effectiveness of this potential new oral treatment in adults aged 18–65 who experience panic attacks but are not currently taking benzodiazepines or affected by other major psychiatric disorders.
Participants will take one oral tablet per day for 12 weeks.
This is a placebo- and comparator-controlled trial with four different study groups. Each participant will be randomly assigned to one group. The study is blinded, so the study doctor and participants will not know which group they are in to keep the results unbiased.
Eligible participants will receive reimbursement for their time and involvement.